Journal of Korean Diabetes,
Journal Year:
2023,
Volume and Issue:
24(3), P. 111 - 119
Published: Sept. 30, 2023
Most
patients
with
diabetes
mellitus
(DM)
have
dyslipidemia,
which
is
characterized
by
increased
triglycerides,
decreased
high-density
lipoprotein
cholesterol,
and
small
dense
low-density
cholesterol
(LDL-C).
Dyslipidemia
an
important
modifiable
risk
factor
for
cardiovascular
disease
(CVD).
Therefore
active
management
essential.
Despite
its
increasing
prevalence,
the
proportion
of
adequately-controlled
dyslipidemia
small,
efforts
to
improve
this
pattern
are
required.
The
Korean
Diabetes
Association
guidelines
recommend
setting
goals
evaluating
each
patient’s
future
CVD
risk,
including
presence
or
absence
CVD,
target
organ
damage,
major
factors,
duration
DM.
primary
LDL-C
level
below
55
mg/dL
(and
a
reduction
in
50%
more
from
baseline),
70
mg/dL,
100
highest
group
lowest
group,
respectively.
Statins
first-line
drug
choice,
if
not
reached
maximum
tolerable
dose
statin,
combination
therapy
ezetimibe
proprotein
convertase
subtilisin/kexin
type
9
inhibitors
recommended.
In
hypertriglyceridemia,
lifestyle
changes
weight
loss
abstinence
alcohol
very
important,
along
glycemic
control.
Journal of Korean Diabetes,
Journal Year:
2023,
Volume and Issue:
24(3), P. 135 - 140
Published: Sept. 30, 2023
To
prevent
cardiovascular
disease
(CVD),
which
is
one
of
the
ultimate
goals
in
management
patients
with
diabetes,
it
important
to
control
not
only
hyperglycemia,
but
also
modifiable
CVD
risk
factors
such
as
hypertension
and
dyslipidemia.
In
addition,
antiplatelet
agents
should
be
used
under
appropriate
conditions.
It
necessary
evaluate
whether
patient
has
CVD,
degree
other
complications,
presence
comorbidities
or
factors,
duration
diabetes.
this
article,
I
will
review
revised
key
points
8th
edition
Korean
Diabetes
Association
clinical
practice
guidelines
for
dyslipidemia
use
Journal of Korean Diabetes,
Journal Year:
2023,
Volume and Issue:
24(3), P. 111 - 119
Published: Sept. 30, 2023
Most
patients
with
diabetes
mellitus
(DM)
have
dyslipidemia,
which
is
characterized
by
increased
triglycerides,
decreased
high-density
lipoprotein
cholesterol,
and
small
dense
low-density
cholesterol
(LDL-C).
Dyslipidemia
an
important
modifiable
risk
factor
for
cardiovascular
disease
(CVD).
Therefore
active
management
essential.
Despite
its
increasing
prevalence,
the
proportion
of
adequately-controlled
dyslipidemia
small,
efforts
to
improve
this
pattern
are
required.
The
Korean
Diabetes
Association
guidelines
recommend
setting
goals
evaluating
each
patient’s
future
CVD
risk,
including
presence
or
absence
CVD,
target
organ
damage,
major
factors,
duration
DM.
primary
LDL-C
level
below
55
mg/dL
(and
a
reduction
in
50%
more
from
baseline),
70
mg/dL,
100
highest
group
lowest
group,
respectively.
Statins
first-line
drug
choice,
if
not
reached
maximum
tolerable
dose
statin,
combination
therapy
ezetimibe
proprotein
convertase
subtilisin/kexin
type
9
inhibitors
recommended.
In
hypertriglyceridemia,
lifestyle
changes
weight
loss
abstinence
alcohol
very
important,
along
glycemic
control.
